Connect with us

BUSINESS

Zelira Therapeutics Ltd (OTCMKTS:ZLDAF) Signing Nonbinding Agreement With Levin Growing To Develop Cannabinoid Based Chronic Pain Treatment

Published

on

Zelira Therapeutics Ltd (OTCMKTS:ZLDAF) has signed a nonbinding agreement with Levin Growing Pty Ltd for the establishment of a development partnership.

Partnership to develop chronic pain treatment

The company will partner with the Melbourne-based medical cannabis firm to develop a proprietary cannabinoid-based chronic pain treatment in retired and amateur athletes studies, retired athletes are likely to experience chronic pain related to conditions like anxiety and depression due to injuries and physical exertion over lengthy periods. Although there is limited clinical data on medical cannabis as an effective and safe targeted treatment option the cannabinoid-based therapy is likely to benefit retired athletes significantly.

Partnership between Zelira and Levin seeks to conduct clinical trials to address this unmet need. They will undertake the trial at the expense of Levin to evaluate the efficacy and safety of a novel cannabinoid formulation customized for sports-associated chronic pain. The collaboration will exploit the leading intellectual property as well as expertise of Zelira in medical cannabis clinical design. The targeted approach offers a chance to develop a leading brand addressing this widespread and specific unmet need.

Zelira to control marketing rights for North and South America

After the Heads of Agreement becomes binding, Zelira will license a particular formulation to Levin supporting the chronic pain trial in retired sportsmen. Zelira will design and co-ordinate the clinical study with funding from Levin. The study is an expansion of the strategic interests of Zelira in chronic pain. Zelira will control commercialization rights in South America and North America while Levin will retain rights to the rest of world markets.

Levin Chairman, Matt Syme, stated that they are thrilled in the partnership with Zelira, one of the top medical cannabis companies. Syme indicated that the company’s advisory board member and sports administrator, James Brayshaw, has identified various retired athletes suffering from chronic pain. He added that the clinical expertise of Zelira and Levin’s focus on medical cannabis science as a chronic pain treatment gives hope of having a non-addictive paint relieve alternative.

BUSINESS

Trade Creditors Of Nutritional High International Inc (OTCMKTS:SPLIF) Agrees To Convert Payables Into Shares And Warrants

Published

on

Nutritional High International Inc (OTCMKTS:SPLIF) entered a settlement agreement with trade creditors. As per the pact terms, the company will convert trade creditors of CAD 1.159 million into 44.253 million units at $0.025/ unit.

4 months holding period

The unitholders are entitled to receive one share and one SPW (share purchase warrant), which can be exercised on or before December 31, 2020, at $0.05/share.

The holding period for acquired shares is 4 months. CEO of Nutritional High, John Durfy, said the company is excited to complete payables’ settlement. It will help the company to enhance its capital structure.

Kruzo established PSC

Kruzo incorporated Psychedelic Science Corp (PSC) to develop and commercialize products manufactured from naturally available psychedelic compounds. Its products are targeted to treat mental ailments like addiction, depression, anxiety, and obesity.

Dr. Duke Fu joined as president of PSC. He is one of the BCNP (Board Certified Nuclear Pharmacists) in Nevada. As part of the doctorate program, he has experimented cultivation of thirty varieties of fungi. Duke is the CEO and co-founder of a premier manufacturing and cultivation company – Green Therapeutics. Nutritional High agreed to acquire a stake of 75% in Green Therapeutics.  PSC is also on the lookout for a chairman to head its medical advisory board.

PSC raises $1.035 million

PSC raised funds of $1.035 million through a private placement of 34.522 million units at $0.03/ unit.

Each unit comprises one common SPW and one common share. The share purchase warrant holder can acquire a common share at $0.05 within two years from closing this offering.

Gross proceeds for cacti-infused beverage

Commenting on the private placement, John said the deal marks an important milestone for PSC because the commercialization of psychedelics will help the company to satisfy the wellness and health goals of a wide gamut of consumers. He said the gross proceeds of this private placement shall be used to develop flagship product cacti infused and water-based functional beverage and grow business.

Nutritional High will complete the takeover of PSC soon. The science team of Nutritional High is working with Rangsit University and PSC to develop a whole plant study to identify the efficacy of psychedelic cacti micro-dosing.

Continue Reading

BUSINESS

Heritage Cannabis Holdings Corp (OTCMKTS:HERTF) Inks A Pact To Takeover Opticann Inc For CAD 5 Million

Published

on

Heritage Cannabis Holdings Corp (OTCMKTS:HERTF) signed an agreement to clinch all outstanding and issued Opticann Inc shares for an initial sum of CAD 5 million.

Colorado-based topical and oral cannabinoid company – Opticann holds exclusive rights to sell CBG and CBD products manufactured using VESIsorb drug delivery system. VESIsorb is optimized for stability and better absorption.

Additional CAD 30 million

Heritage will also pay additional CAD 30 million in the next five years up on Opticann, achieving certain enterprise and financial milestones. MedReleaf Corp’s former executives established Opticann.

Supply and distribution accord

Opticann holds a supply and distribution pact with Geocann LLC, which holds sole rights to VESIsorb technology for flavonoid formulations, terpenes, and cannabinoids. Opticann will own the brand’s sole distribution rights and sell VESIsorb formulated topical and oral cannabigerol and cannabidiol products to prominent retailers in the US.

What is VESIsorb?

It is an innovative drug delivery system to ensure the bioavailability and stability of natural ingredients such as CBD. The results obtained from a cross-over and double-blind trial show that CBD absorption formulated using VESIsorb is significantly improved compared to cannabidiol extracts formulated using MCT oil.

Chairman of Opticann, Neil Closner, said the patented VESIsorb technology allows creating innovative CBD and cannabidiol products that excel in performance compared to other market products. The company manufactures these innovative products in its GMP certified and scalable supply chain to build brands targeting large retailers in the US. Neil is excited to welcome the team at Opticann along with its patented technology to its fold and execute the plan.

Clint Sharples said the takeover of Opticann is a prudent step because it expands the expertise and improves its presence in the US. The takeover helps the company to capture a significant share of the multi-billion CBD market in the US. He further said the company is pleased to accept Opticann into its family and embrace proven and talented team members and cannabis executives from earlier MedReleaf. Heritage will also benefit from the relationships established and experience gained in the international space because it plans to expand its presence worldwide.

Continue Reading

BUSINESS

Zelira Therapeutics Ltd (OTCMKTS:ZLDAF) Inks A Pact With CSCM To Develop Products To Treat Health Risks And Symptoms In Patients With Diabetes And Cardiovascular Disease

Published

on

Zelira Therapeutics Ltd (OTCMKTS:ZLDAF) signed a deal with Cardiovascular Solutions of Central Mississippi (CSCM) to help patients with cardiovascular diseases and diabetes by offering innovative products. The new products developed using CBD derived from hemp and other cannabinoids exclusively for CSCM will address therapeutics needs related to patients with DPN (Diabetic Neuropathies) and PAD (Peripheral Arterial Disease).

Upfront license fee payment to Zelira

CSCM will pay an upfront license fee to Zelira. It will also pay royalties to Zelira on the commercialization of the products developed under this agreement. The company will also bear all the expenses related to marketing, manufacturing, distribution, and sale of US products.

CSCM holds exclusive marketing rights for all the products developed by Zelira as per this deal in the US markets. However, Zelira retains marketing rights for developed products in other markets across the world.

Several people are suffering from lower-limb amputations, adult blindness, and kidney failure in the US because of diabetes. According to CDC, of the 30 million Americans who have diabetes in the US, one among the three adults aged above 50 years develops PAD.

Peripheral Arterial Disease is the chief cause of non-traumatic amputations in the US. DPN, which is the most common health condition related to diabetes, is the chief cause of disability, mainly due to fall risks and foot ulcerations. If it is not cured in time, it could lead to limb amputation and infection as well.

The annual spending on diabetic treatment is $326 billion in the US. According to a recent CDC (Centers for Disease Control) projection, one in three people in the US will suffer from diabetes by the year 2050. Ethnic and racial minorities in the US usually suffer from higher health care costs.

CEO of CSCM, Dr. Foluso Fakorede, said the company is excited to enter a deal with Zelira to develop effective and innovative treatment options for patients suffering from PAD. This partnership’s main target is to develop and promote the treatment for cardiovascular disease and address unmet needs for marginalized communities.

Zelira will also focus on unveiling its HOPE Products and proprietary Zenivol in the international markets.

Continue Reading

Trending Stories